Skip to main content
22 search results for:

Anifrolumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 23-02-2022 | Systemic lupus erythematosus | News | Article

    Anifrolumab benefits extend across multiple organ domains in SLE

    A post-hoc analysis of data from the TULIP-1 and TULIP-2 trials suggests that anifrolumab treatment improves disease activity across different organ systems among people with moderate-to-severe systemic lupus erythematosus.

  2. 15-02-2022 | Lupus nephritis | News | Article

    Intensified anifrolumab regimen may warrant further investigation for lupus nephritis

    Findings from the phase 2 TULIP-LN trial suggest that add-on treatment with an intensified regimen of anifrolumab, a type I interferon receptor inhibitor, may improve some outcomes for patients with lupus nephritis.

  3. 20-12-2021 | Systemic lupus erythematosus | News | Article
    approvalsWatch

    Anifrolumab set for EMA approval for moderate-to-severe SLE

    The benefits of anifrolumab were shown in the phase 3 TULIP-1  and TULIP-2  trials, which demonstrated an overall improvement in clinical measures with anifrolumab versus placebo, even though the TULIP-1 trial did not meet its primary endpoint.

  4. 06-09-2021 | Pneumonia | Teaser

    Anifrolumab for the treatment of lupus

    Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

  5. 06-09-2021 | Systemic lupus erythematosus | Video | Article

    FDA approval of anifrolumab for SLE

    Eric Morand gives his thoughts on the FDA approval of anifrolumab for SLE and discusses the need for additional studies to understand exactly how the drug should be used in routine clinical practice

  6. 04-08-2021 | Systemic lupus erythematosus | News | Article

    FDA approves anifrolumab for moderate-to-severe SLE

    medwireNews : The US FDA has approved anifrolumab-fnia for the treatment of adult patients with moderate-to-severe systemic lupus erythematosus (SLE) who are receiving standard therapy.

  7. 30-11-2020 | Systemic lupus erythematosus | News | Article

    Subcutaneous delivery feasible for anifrolumab in SLE

    Phase 2 study data suggest that subcutaneous administration is a feasible option for treatment with the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus.

  8. 13-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Article

    TULIP-2 meets primary endpoint for anifrolumab efficacy in SLE

    Anifrolumab has shown clinical efficacy in systemic lupus erythematosus, based on BICLA response as the primary outcome, TULIP-2 results show.

  9. 11-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Article

    TULIP-1 results fail to support phase II findings for anifrolumab in SLE

    The first phase III trial of anifrolumab has failed to show a significant overall benefit for patients with systemic lupus erythematosus when taken in addition to standard care, but does demonstrate some clinical response improvements that the researchers say deserve further investigation.

  10. 25-08-2021 | Anifrolumab | Channel

    Anifrolumab for the treatment of SLE

    Learn about approval of anifrolumab for SLE treatment with summaries of the TULIP trial results and discussion on the importance of trial endpoints.

  11. 10-07-2021 | Adis Journal Club | Article
    Pediatric Drugs

    An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus

    Anti-interferon therapies (sifalimumab and anifrolumab) have shown beneficial results in adult SLE patients, as have Janus kinase inhibitors, and could in the future be an alternative treatment for pediatric patients with severe interferon-mediated inflammatory disease.

  12. 07-04-2020 | Systemic lupus erythematosus | Feature | Article

    In pursuit of new lupus therapies: The importance of trial endpoints

    Eric Morand explores the reasons why the TULIP-1 and TULIP-2 trials of anifrolumab found different primary results, and discusses the search for optimal endpoints in lupus trials.

  13. 04-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Teaser

    The TULIP trials

    News story |  TULIP-1 results fail to support phase II findings for anifrolumab in SLE News story |  TULIP-2 meets primary endpoint for anifrolumab efficacy in SLE

  14. 18-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Article

    No benefit of add-on fenebrutinib for patients with SLE

    ACR 2019 news: Phase II trial results suggest no benefit of anifrolumab for patients with lupus.

  15. 07-04-2020 | Systemic lupus erythematosus | Infographic | Image

    The TULIP-1 and TULIP-2 trials

    Primary and key secondary outcome results from the TULIP-1 and TULIP-2 trials of anifrolumab.

  16. 18-10-2019 | Teaser

    TULIP-1

    TULIP-1 is a phase III trial of add-on anifrolumab versus placebo for the treatment of moderate-to-severe systemic lupus erythematosus. Monday, November 11, 11:00–12:30

  17. 16-01-2020 | Systemic lupus erythematosus | News | Article

    Further study warranted for IFN-K in SLE

    Discussing their findings, the authors point out that it “has been increasingly acknowledged” that failures of type I IFN-targeted agents such as rontalizumab, sifalimumab, and anifrolumab, in phase 3 clinical trials “may be more related to the choice of the outcome measures than to actual inefficacy of the molecules.”

  18. The TULIP-1 trial

    registrationCTA Monday 11 November: 11:00–12:30, Hall B1, Georgia World Congress Center, Atlanta, USA Presenter: Richard Furie, Zucker School of Medicine at Hofstra/Northwell, New York, USA In the phase III TULIP-1 study, patients with moderate-to-severe systemic lupus erythematosus were randomly assigned to receive intravenous anifrolumab – a human monoclonal antibody that binds the type I interferon receptor – at a dose of 150 mg or 300 mg every 4 weeks or placebo in addition to standard-of-care treatment.

  19. 20-06-2019 | Systemic lupus erythematosus | Highlight | Article

    Systemic lupus erythematosus: Novel therapies and targeted treatments

    Anifrolumab Anifrolumab is a monoclonal antibody blocking the type I interferon (IFN)-α/β/ω receptor.

  20. 13-08-2019 | Systemic lupus erythematosus | Editorial | Article

    Neuropsychiatric systemic lupus erythematosus: Issues in diagnosis and management

    In this study, mice treated with the type I IFN receptor-blocking antibody anifrolumab exhibited attenuation of CNS disease.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.